| Symbol | ACHV |
|---|---|
| Name | ACHIEVE LIFE SCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Address | 22722 29TH DRIVE SOUTHEAST,SUITE 100, BOTHELL, British Columbia, WA 98021, Canada |
| Telephone | +1 604 210-2217 |
| Fax | — |
| — | |
| Website | https://www.achievelifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000949858 |
| Description | Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieves focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Additional info from NASDAQ: |
2026-07-08 17:33
New Form SCHEDULE 13G - ACHIEVE LIFE SCIENCES, INC. <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0001213900-26-076390 <b>Size:</b> 32 KB
Read more
2026-07-06 20:06
(99% Neutral) ACHIEVE LIFE SCIENCES, INC. (ACHV) Announces Regulatory Update
Read more
2026-06-22 12:30
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
Read more
2026-06-22 12:30
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
Read more
2026-06-08 17:07
New Form ARS - ACHIEVE LIFE SCIENCES, INC. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0000949858-26-000007 <b>Size:</b> 798 KB
Read more
2026-06-08 17:06
New Form DEF 14A - ACHIEVE LIFE SCIENCES, INC. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0000949858-26-000006 <b>Size:</b> 13 MB
Read more
2026-06-02 20:13
Waldman Reid Alexander 🟢 acquired 47.2K shares (1 derivative) of ACHIEVE LIFE SCIENCES, INC. (ACHV) at $5.24 Transaction Date: May 29, 2026 | Filing ID: 000004
Read more
2026-06-02 20:12
Farrow Jeffrey S 🟢 acquired 47.2K shares (1 derivative) of ACHIEVE LIFE SCIENCES, INC. (ACHV) at $5.24 Transaction Date: May 29, 2026 | Filing ID: 000011
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07392125 | Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Ce… | Phase3 | Vaping Cessation | Not_Yet_Recruiting | 2026-05-15 | 2027-09-30 | ClinicalTrials.gov |
| NCT06435221 | Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers | Phase3 | Smoking Cessation | Completed | 2024-05-28 | 2025-10-06 | ClinicalTrials.gov |
| NCT05981768 | Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and P… | Phase1 | Smoking Cessation | Completed | 2023-08-08 | 2023-09-21 | ClinicalTrials.gov |
| NCT05631938 | Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the … | Phase1 | Renal Impairment | Completed | 2023-01-10 | 2023-09-04 | ClinicalTrials.gov |
| NCT05566288 | Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeuti… | Phase1 | Smoking Cessation | Completed | 2022-10-17 | 2022-12-23 | ClinicalTrials.gov |
| NCT05431387 | A Study of Cytisinicline for Vaping Cessation in Adult Smokers | Phase2 | Vaping | Completed | 2022-07-13 | 2023-02-28 | ClinicalTrials.gov |
| NCT05206370 | A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers | Phase3 | Smoking Cessation | Completed | 2022-01-20 | 2023-03-21 | ClinicalTrials.gov |
| NCT04576949 | A Study of Cytisinicline for Smoking Cessation in Adult Smokers | Phase3 | Smoking Cessation | Completed | 2020-10-13 | 2021-12-23 | ClinicalTrials.gov |
| NCT03848208 | A Single Dose-escalation Study of Cytisine in Adult Smokers | Phase1 | Smoking Cessation | Completed | 2019-02-28 | 2019-09-12 | ClinicalTrials.gov |
| NCT03709823 | Trial of Cytisine in Adult Smokers | Phase2 | Smoking Cessation | Completed | 2018-11-13 | 2019-04-23 | ClinicalTrials.gov |
| NCT03509948 | A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailabi… | Phase1 | Smoking Cessation | Completed | 2018-04-27 | 2018-06-12 | ClinicalTrials.gov |
| NCT03303911 | A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers | Phase1 | Smoking Cessation | Terminated | 2017-10-06 | 2018-10-05 | ClinicalTrials.gov |
| NCT03268343 | A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavail… | Phase1 | Smoking Cessation | Completed | 2017-08-08 | 2017-09-01 | ClinicalTrials.gov |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advan… | Phase2 | Squamous Cell Lung Cancer | Unknown | 2014-06-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT01874561 | Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirs… | Phase1 | Cardiac Conduction and Repolarization | Completed | 2013-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory … | Phase2 | Bladder Cancer | Completed | 2013-04-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific… | Phase2 | Prostate Cancer | Terminated | 2012-12-01 | 2017-06-21 | ClinicalTrials.gov |
| NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Adv… | Phase3 | Non-Small Cell Lung Cancer | Completed | 2012-10-24 | 2016-11-17 | ClinicalTrials.gov |
| NCT01578655 | Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for… | Phase3 | Prostate Cancer | Completed | 2012-08-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01497470 | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Cust… | Phase1 | Cancer | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01454089 | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo i… | Phase2 | Urologic Neoplasms | Completed | 2011-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01188187 | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With … | Phase3 | Prostate Cancer | Completed | 2010-11-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01120470 | OGX-427 in Castration Resistant Prostate Cancer Patients | Phase2 | Castration Resistant Prostate Cancer | Completed | 2010-09-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01083615 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel… | Phase3 | Castrate-Resistant Prostate Cancer | Terminated | 2010-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00487786 | Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Blad… | Phase1 | Neoplasms | Completed | 2007-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00385177 | Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Ad… | Phase1 | Breast Neoplasms | Completed | 2006-09-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00327340 | Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Ch… | Phase2 | Prostate Cancer | Completed | 2006-07-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00251095 | Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for … | Phase3 | Breast Neoplasm | Terminated | 2005-09-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00138658 | A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Smal… | Phase1 | Non-small Cell Lung Cancer | Completed | 2004-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00096668 | Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment… | Phase2 | Breast Cancer | Completed | 2004-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitio… | Phase2 | Bladder Neoplasms | Completed | 2003-11-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00034177 | Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or … | Phase2 | Urologic Neoplasms | Completed | 2002-04-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00034164 | Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB o… | Phase2 | Carcinoma, Non-Small-Cell Lung | Completed | 2002-04-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00034151 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovari… | Phase2 | Ovarian Cancer | Completed | 2002-03-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00034190 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Color… | Phase2 | Colorectal Adenocarcinoma | Completed | 2002-03-01 | 2007-09-01 | ClinicalTrials.gov |
Total clinical trials: 35
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| custirsen sodium | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01578655 |
| prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01578655 |
| cabazitaxel | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01578655 |
| Cytisine | Other | Phase PHASE1 | Smoking Cessation | TERMINATED | NCT03303911 |
| Docetaxel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT01780545 |
| OGX-427 | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT01780545 |
| Carboplatin | Other | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| Cisplatin | Other | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| Gemcitabine | Other | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| Placebo | Other | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| OGX-427 1000 mg | Other | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| OGX-427 600 mg | Other | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| Moxifloxacin | Other | Phase PHASE1 | Cardiac Conduction and Repolarization | COMPLETED | NCT01874561 |
| Placebo | Other | Phase PHASE1 | Cardiac Conduction and Repolarization | COMPLETED | NCT01874561 |
| Custirsen | Other | Phase PHASE1 | Cardiac Conduction and Repolarization | COMPLETED | NCT01874561 |
| Custirsen, paclitaxel and carboplatin | Other | Phase PHASE1 | Cancer | COMPLETED | NCT01497470 |
| prednisone | Other | Phase PHASE3 | Castrate-Resistant Prostate Cancer | TERMINATED | NCT01083615 |
| cabazitaxel | Other | Phase PHASE3 | Castrate-Resistant Prostate Cancer | TERMINATED | NCT01083615 |
| docetaxel | Other | Phase PHASE3 | Castrate-Resistant Prostate Cancer | TERMINATED | NCT01083615 |
| isotonic, 0.9% sodium chloride | Other | Phase PHASE3 | Castrate-Resistant Prostate Cancer | TERMINATED | NCT01083615 |
| custirsen sodium | Other | Phase PHASE3 | Castrate-Resistant Prostate Cancer | TERMINATED | NCT01083615 |
| Dexamethasone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01188187 |
| Prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01188187 |
| Docetaxel | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01188187 |
| Custirsen | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01188187 |
| Carboplatin | Other | Phase PHASE2 | Squamous Cell Lung Cancer | UNKNOWN | NCT02423590 |
| Gemcitabine | Other | Phase PHASE2 | Squamous Cell Lung Cancer | UNKNOWN | NCT02423590 |
| Apatorsen (OGX-427) | Other | Phase PHASE2 | Squamous Cell Lung Cancer | UNKNOWN | NCT02423590 |
| Prednisone | Other | Phase PHASE2 | Castration Resistant Prostate Cancer | COMPLETED | NCT01120470 |
| OGX-427 | Other | Phase PHASE2 | Castration Resistant Prostate Cancer | COMPLETED | NCT01120470 |
| Cytisine | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT03268343 |
| cytisine | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT03509948 |
| Behavioral support | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03709823 |
| Placebo Comparator | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03709823 |
| Cytisine | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03709823 |
| placebo | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT03848208 |
| cytisine | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT03848208 |
| Prednisone | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01681433 |
| Abiraterone Acetate | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01681433 |
| OGX-427 | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01681433 |
| Moxifloxacin | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT05566288 |
| Placebo | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT05566288 |
| Cytisinicline | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT05566288 |
| Cytisinicline | Other | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT05981768 |
| cytisinicline | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05631938 |
| Behavioral support | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT04576949 |
| Placebo | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT04576949 |
| Cytisinicline | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT04576949 |
| Cytisinicline | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT06435221 |
| Behavioral support | Other | Phase PHASE2 | Vaping | COMPLETED | NCT05431387 |
| Placebo | Other | Phase PHASE2 | Vaping | COMPLETED | NCT05431387 |
| cytisinicline | Other | Phase PHASE2 | Vaping | COMPLETED | NCT05431387 |
| Behavioral support | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT05206370 |
| Placebo | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT05206370 |
| Cytisinicline | Other | Phase PHASE3 | Smoking Cessation | COMPLETED | NCT05206370 |
| Docetaxel | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | COMPLETED | NCT01630733 |
| Custirsen | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | COMPLETED | NCT01630733 |
| Behavioral Support | BEHAVIORAL | Phase PHASE3 | Vaping Cessation | NOT_YET_RECRUITING | NCT07392125 |
| cytisinicline | DRUG | Phase PHASE1 | Renal Impairment | COMPLETED | NCT05631938 |
| Cytisinicline | DRUG | Phase PHASE3 | Vaping Cessation | NOT_YET_RECRUITING | NCT07392125 |
| placebo | DRUG | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT03848208 |
| Behavioral support | BEHAVIORAL | Phase PHASE2 | Vaping | COMPLETED | NCT05431387 |
| Placebo Comparator | DRUG | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03709823 |
| cytisine | DRUG | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT03848208 |
| Cytisine | DRUG | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT03709823 |
| Apatorsen (OGX-427) | DRUG | Phase PHASE2 | Squamous Cell Lung Cancer | UNKNOWN | NCT02423590 |
| Moxifloxacin | DRUG | Phase PHASE1 | Smoking Cessation | COMPLETED | NCT05566288 |
| Abiraterone Acetate | DRUG | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01681433 |
| Custirsen, paclitaxel and carboplatin | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT01497470 |
| Carboplatin | DRUG | Phase PHASE2 | Squamous Cell Lung Cancer | UNKNOWN | NCT02423590 |
| Cisplatin | DRUG | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| Gemcitabine | DRUG | Phase PHASE2 | Squamous Cell Lung Cancer | UNKNOWN | NCT02423590 |
| Placebo | DRUG | Phase PHASE3 | Vaping Cessation | NOT_YET_RECRUITING | NCT07392125 |
| OGX-427 1000 mg | DRUG | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| OGX-427 600 mg | DRUG | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT01454089 |
| Dexamethasone | DRUG | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01188187 |
| Custirsen | DRUG | Phase PHASE1 | Cardiac Conduction and Repolarization | COMPLETED | NCT01874561 |
| Prednisone | DRUG | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01681433 |
| prednisone | DRUG | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01578655 |
| cabazitaxel | DRUG | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01578655 |
| docetaxel | DRUG | Phase PHASE3 | Castrate-Resistant Prostate Cancer | TERMINATED | NCT01083615 |
| isotonic, 0.9% sodium chloride | DRUG | Phase PHASE3 | Castrate-Resistant Prostate Cancer | TERMINATED | NCT01083615 |
| Docetaxel | DRUG | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT01780545 |
| OGX-427 | DRUG | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01844817 |
| SN2310 Injectable Emulsion | DRUG | Phase PHASE1 | Breast Neoplasms | COMPLETED | NCT00385177 |
| custirsen (OGX-011)/docetaxel | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00327340 |
| custirsen (OGX-011)/mitoxantrone | DRUG | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT00327340 |
| TOCOSOL Paclitaxel | DRUG | Phase PHASE3 | Breast Neoplasm | TERMINATED | NCT00251095 |
| Taxol | DRUG | Phase PHASE3 | Breast Neoplasm | TERMINATED | NCT00251095 |
| custirsen sodium | DRUG | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01578655 |
| TOCOSOL(R) Paclitaxel | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00096668 |
| Experimental Arm: TOCOSOL Paclitaxel | DRUG | Phase PHASE2 | Urologic Neoplasms | COMPLETED | NCT00034177 |
| S-8184 Paclitaxel Injectable Emulsion | DRUG | Phase PHASE2 | Colorectal Adenocarcinoma | COMPLETED | NCT00034190 |
Total products: 93